CFTR and End Stage Liver Disease: Median model for end-stage liver disease-sodium scores were higher among individuals waitlisted following the approval of dual (9 [6–14] vs 10 [8–15], P < .013) and triple (9 [6–14] vs 12.5 [8–17], P < .003) CFTR modulators.